GlassScriptPhysician profile
Edward Heilman
NPI 1144209701
$3,462.52
in general payments reported to CMS, 2019-2025
25 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $499 · 2021: $273 · 2022: $49.42 · 2023: $320 · 2024: $894 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $779.49 | 2019-2025 | Tremfya |
| Genzyme Corporation | $412.45 | 2019-2025 | |
| Abbvie INC. | $339.70 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $253.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $241.80 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $222.76 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $155.32 | 2020-2025 | Ebglyss, Olumiant, Taltz |
| Helsinn Therapeutics (U.S.), INC. | $153.77 | 2021-2024 | Valchlor |
| Galderma Laboratories, L.P. | $121.38 | 2025 | Nemluvio |
| Pfizer INC. | $103.14 | 2019-2024 | |
| Leo Pharma INC. | $100.37 | 2023-2025 | Adbry, Anzupgo |
| Sanofi-Aventis U.S. LLC | $73.72 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $69.84 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $67.28 | 2023-2024 | Vtama |
| Nobelpharma America, LLC | $65.84 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $48.73 | 2021 | |
| Amgen INC. | $48.36 | 2023-2025 | Amjevita |
| Regeneron Healthcare Solutions, INC. | $35.39 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $32.71 | 2025 | Acthar |
| Ucb, INC. | $27.43 | 2021 | |
| Lnhc, INC | $26.67 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.48 | 2025 | Spevigo |
| Organon LLC | $23.09 | 2025 | Vtama |
| Incyte Corporation | $19.43 | 2021 | |
| Dermira, INC. | $14.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Heilman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.